Document is current

Article History

Received: 23 July 2022

Accepted: 12 September 2022

First Online: 29 September 2022

Declarations

:

: SI none. TK has received speaking fees and/or honoraria from Tanabe. Mitsubishi, Kissei, Pfizer, Amgen, Chugai, Daiichi-Sankyo, Eli Lilly, Novartis, and Janssen, and received grants and speaking fees from GlaxoSmithKline. HS has received fees from Pfizer, Bristol-Myers Squibb, Eli Lilly, Sanofi, AbbVie, GlaxoSmithKline, Gilead, Boehringer Ingelheim, Jansen, Novartis, Chugai, Takeda, Astellas, Eisai, Asahi Kasei, Taisho Pharmaceutical, Astrazeneca and Daiichi-Sankyo. KF has received speaking fees and/or honoraria from Tanabe Mitsubishi, Bristol-Myers Squibb, Eli Lilly, Chugai, Jansen, Pfizer, Ono, AbbVie, Ayumi, Astellas, Sanofi, Novartis, Daiichi Sankyo, Eisai, Asahi Kasei, and AstraZeneca and has received research grants from Tanabe Mitsubishi, Bristol-Myers Squibb, Eli Lilly, Chugai, Eisai, Tsumura, and Asahi Kasei.

: This study was conducted upon the approval of the Ethical Committee of the University of Tokyo Hospital (approval number, 2431; February 20, 2009).

: Patients and/or the public were not involved in the design, analysis, reporting, or dissemination plans of this research.

: Not required.